pfizer

I am in R&D (PRD, remote approved, GT site). Has anyone heard anything from your managers on whether you are impacted? also I thought PGS mfg sites was not going to be impacted but saw news about Kalamazoo 200 head count news today

It would be great for some of us to share our thoughts and feelings regarding the cuts in the PAXLOVID/Comirnaty/Prevnar/Lucira contract. I feel that there were lies and misrepresentation regarding the situation up until the fateful Friday calls. How about you?

I have spoken to so many HCPs who said they haven't heard a peep from Pfizer about anything COVID.

I am considering a position as a sales rep with Pfizer. Can anyone share what resources are currently being made available to employees (iPad model, other technology, etc.) and what your experience has been like over the last few years? How many calls/interactions are you expected to make per...

What’s going to happen to our Volvos? Lol I sold my personal car when I got hired in Spring 2021. I'm scared, not gonna lie.

The poor bedraggled Internal Medicine team. Two years ago at this time we had 3 - count em, 3 IM teams. First it was Team 3; gone. A year later all of Team 1. Now it's Team 2's turn. My question is - how many people are left in IM? I'm in a different division now but still get IM emails so...

boss said he heard something like that :O

C3 just the beginning! Hundreds more reps to be cut. Very sad!!!

Mylan N.V. (MYL) reported its financial results for the quarter ended March 31, 2020, on Monday before the market opens. The company reaffirmed its financial guidance for the full-year 2020. The results were driven by overall volume growth, which was favorably impacted by increased customer...

With Viagra patents expired does it make sense for Pfizer to buy Vyleesi rights?

Total revenues declined 5% year-over-year to $12.68 billion from $13.3 billion in the third quarter of 2018. Segment-wise, Biopharma revenues grew 7% annually to $10.1 billion, while Upjohn revenues dropped 26% to $2.19 billion. Consumer Healthcare revenues were down 55%. Pfizer management...

Novo Nordisk says pricing pressure within diabetes to continue, especially in the US. First quarter 2019 results: Sales from North America Operations declined 4% on constant exchange rates.

Pfizer (PFE) reported a better-than-expected 2% increase in fourth-quarter revenues to $13.9 billion. Earnings rose to 64 cents per share from 62 cents per share a year ago, surpassing analysts’ estimate of 63 cents per share. PFE shares were down 3% during pre-market trading on Tuesday. Shares...

So the rumormill is churning about potential bid coming from Pfizer. Have any employees heard any rumblings about this yet?

Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/

Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?

I expect that Amarin will bounce back from the recent sell-off. Most of the doctors who participated in the AHA event has said that they will prescribe Vascepa and next year the biggies like Pfizer might considering acquiring Amarin...

Does this happen often? Stories?

There are rumors that Pfizer would take over Amarin, which skyrocketed today in the stock market as the cardiovascular study met primary and secondary endpoints using Vascepa drug. But Amarin has said that it's just a speculation...

Pfizer Inc. reported a rise in earnings for the second quarter, helped by the strength of its anchor brands, primarily Ibrance, Eliquis, and Xeljanz. The top and bottom lines came in above analysts’ expectations. Revenue improved by 4% driven by the continued growth of key brands, as well as...